Insulet Corporation $PODD Shares Purchased by denkapparat Operations GmbH

denkapparat Operations GmbH boosted its position in Insulet Corporation (NASDAQ:PODD) by 310.1% in the 2nd quarter, according to its most recent filing with the SEC. The firm owned 9,104 shares of the medical instruments supplier’s stock after acquiring an additional 6,884 shares during the period. denkapparat Operations GmbH’s holdings in Insulet were worth $1,386,000 at the end of the most recent reporting period.

Several other institutional investors also recently bought and sold shares of the business. Larson Financial Group LLC boosted its holdings in shares of Insulet by 114.6% during the fourth quarter. Larson Financial Group LLC now owns 88 shares of the medical instruments supplier’s stock worth $25,000 after purchasing an additional 47 shares during the last quarter. University of Texas Texas AM Investment Management Co. acquired a new position in Insulet in the fourth quarter valued at $26,000. Elyxium Wealth LLC acquired a new position in Insulet in the fourth quarter valued at $28,000. DV Equities LLC purchased a new position in Insulet during the fourth quarter worth about $28,000. Finally, MV Capital Management Inc. purchased a new position in Insulet during the fourth quarter worth about $29,000.

Analyst Ratings Changes

Several research firms have commented on PODD. Stifel Nicolaus lowered their price target on Insulet from $225.00 to $180.00 and set a “buy” rating for the company in a report on Thursday, August 6th. TD Cowen cut their price objective on shares of Insulet from $294.00 to $144.00 and set a “hold” rating on the stock in a report on Thursday, August 6th. Wells Fargo & Company cut shares of Insulet from an “overweight” rating to an “equal weight” rating and decreased their target price for the stock from $255.00 to $144.00 in a research report on Wednesday, August 5th. JPMorgan Chase & Co. reissued a “neutral” rating and issued a $152.00 target price (down from $275.00) on shares of Insulet in a research report on Thursday, August 6th. Finally, Wall Street Zen downgraded shares of Insulet from a “strong-buy” rating to a “hold” rating in a report on Sunday, August 9th. Fourteen research analysts have rated the stock with a Buy rating, eleven have assigned a Hold rating and two have given a Sell rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Hold” and a consensus price target of $195.40.

Insulet Stock Performance

Shares of NASDAQ:PODD opened at $150.58 on Friday. The firm has a market capitalization of $10.44 billion, a PE ratio of 28.15, a P/E/G ratio of 1.17 and a beta of 1.08. The company has a debt-to-equity ratio of 0.65, a current ratio of 2.48 and a quick ratio of 1.83. The business has a 50-day moving average of $154.66 and a two-hundred day moving average of $177.94. Insulet Corporation has a 12 month low of $126.40 and a 12 month high of $354.88.

Insulet (NASDAQ:PODD) last released its quarterly earnings data on Wednesday, August 5th. The medical instruments supplier reported $1.66 EPS for the quarter, topping analysts’ consensus estimates of $1.47 by $0.19. The company had revenue of $801.70 million for the quarter, compared to the consensus estimate of $787.39 million. Insulet had a return on equity of 29.29% and a net margin of 12.29%.The company’s quarterly revenue was up 23.5% compared to the same quarter last year. During the same period last year, the business posted $1.17 EPS. Insulet has set its FY 2026 guidance at 6.460- EPS. As a group, research analysts forecast that Insulet Corporation will post 6.51 earnings per share for the current year.

Insulet Profile

Insulet Corporation is a medical device company headquartered in Acton, Massachusetts, that develops, manufactures and sells insulin-delivery systems for people with diabetes. The company’s core business is the design and commercialization of its Omnipod family of tubeless, wearable insulin pumps and the consumable Pods that deliver insulin. Insulet’s products aim to simplify insulin delivery for people with type 1 diabetes and insulin-requiring type 2 diabetes by offering an alternative to traditional insulin pens and tethered pump systems.

The company’s product portfolio includes the Omnipod System line—disposable, waterproof Pods that adhere to the skin and deliver insulin—and the associated controllers and mobile applications used to program and monitor insulin delivery.